Evidence suggests an association between brain ischemia and Alzheimer's disease (AD) development. Amyloid plaques consisted of β-amyloid peptide (Aβ) in the brain are a pathological hallmark of AD. Little is known about how brain ischemia induces AD-like neuropathology. A strategy effective to block such brain changes has not been reported. Here, adult male Sprague-Dawley rats were subjected to a 90-min right middle cerebral artery occlusion (MCAO). Pyrrolidine dithiocarbamate (PDTC) at various doses was given daily via gastric gavage with the first dose given at 10 min after the onset of reperfusion. The MCAO increased Aβ1-42 concentrations in the ischemic brain tissues. PDTC attenuated this increase. PDTC also decreased the ischemia-reduced expression of neprilysin, an Aβ degrading enzyme. Aβ1-42 levels were negatively correlated with neprilysin protein abundance. Brain ischemia decreased the expression of β-amyloid converting enzyme 1, a key enzyme to produce Aβ, and increased the expression of insulin-degrading enzyme, another Aβ degrading enzyme. Animals had impaired learning and memory at 2 months after the MCAO. PDTC attenuated this impairment. PDTC also improved long-term neurological outcomes. Our findings suggest that PDTC improves long-term neurological outcome of rats after transient focal brain ischemia. PDTC reduces ischemia-induced Aβ accumulation, possibly via preserving neprilysin expression.
Introduction
Ischemic brain injury is the underlying pathophysiology for many common human diseases, such as stroke and brain trauma (Martin et al., 1999) . A long-term effect of brain ischemia is cognitive impairment. It has been shown that 29% of patients develop new onset dementia in 3 years after a stroke (Henon et al., 2001 ).
Alzheimer's disease (AD) is the most common form of dementia in the elderly. Brain ischemia significantly increases the risk of AD (Tatemichi et al., 1992; Vermeer et al., 2003) . One pathological hallmark in the brain of a patient with AD is extracellular amyloid plaques formed by accumulated β-amyloid peptide (Aβ) (Selkoe, 2001) , an enzymatic product of amyloid precursor protein (APP) by β-secretase/β-amyloid converting enzyme 1 (BACE1) and γ-secretase (Vassar and Citron, 2000) . The popular amyloid cascade hypothesis states that generation and accumulation of Aβ are the central event for developing AD (Selkoe, 2000) . It has been suggested that Aβ induces local neurotoxicity that ultimately results in AD.
Although clinical evidence has suggested a strong association between brain ischemia and AD and animal studies have shown that brain ischemia induces learning and memory impairment (Heim et al., 2000; Takeo et al., 2003) , it is just beginning to reveal the mechanisms for brain ischemia to lead to AD neuropathology. Earlier studies have shown that ischemia increases APP accumulation in the astrocytic processes and neuronal axons of ischemic tissues (Kalaria et al., 1993; Stephenson et al., 1992) . Recent evidence has suggested that brain ischemia in animals increases the expression of BACE1 (Tesco et al., 2007; Wen et al., 2004) . BACE1 is the rate-limited enzyme for the proteolytic cleavage of APP in the amyloidogenic pathway. A recent study has shown that brain ischemia increases the Aβ accumulation in human brain (Qi et al., 2007) . However, strategy that is effective to block brain ischemia-induced AD-like brain pathology has not been reported.
Pyrrolidine dithiocarbamate (PDTC) is an anti-oxidant and antiinflammatory agent (Liu et al., 1999) . PDTC reduces focal brain ischemic injury (Nurmi et al., 2004b) . PDTC also improves learning and memory functions of transgenic mice modeling for AD (Malm et al., 2007) . Thus, we hypothesize that PDTC attenuates AD-like brain changes after focal brain ischemia.
